Healthcare providers may opt to utilize gastrointestinal prokinetics such as metoclopramide to counteract the digestive slowdown and ensure a sedative or anesthetic is effectively distributed throughout the body
Statistical analysis For each study population, the semaglutide cohort and the comparision cohort were propensity-score matched (1:1 using nearest neighbor greedy matching with a caliper of 0.25 times the standard deviation) on covariates that are potential risk factors for AUD 57,58,59,60 including demographics, adverse socioeconomic determinants of health (e.g., problems related to education and literacy, employment and unemployment, housing and economic circumstances, social environment, upbringing, primary support group including family circumstances and various psychosocial circumstances), problems with lifestyle (e.g., tobacco use, lack of physical exercise, inappropriate diet and eating habits, high-risk sexual behavior, gambling and betting, and other problems related to lifestyle including antisocial behaviors and sleep deprivation), pre-existing medical conditions, medications, medical procedures and medical visit types (outpatient, inpatient, emergency, and virtual)
Date: June 16, 2026 Source: The Endocrine Society Summary: A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while delivering greater weight loss
There are disputes over how concerning this should be as a side effect, but some studies show as much as 40 to 60 percent of the total weight loss on GLP-1 drugs comes from lean muscle mass
